Moberg Pharma
Moberg Pharma: Positive surprises (Redeye)

2019-10-01 08:04
Management once again demonstrates its commitment to building shareholder value by signing yet another significant licensing agreement for MOB-015. The deal with Taisho providing cash, making it possible to raise the shareholder payment to SEK 46.50 from the previously announced interval of SEK 43-45, but also to repay outstanding debt.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Moberg Pharma - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -